Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

Vical’s cancer immunotherapy fails in late-stage trial

Allovectin no better than standard chemotherapy

Roche - Basel

Roche’s Erivedge authorised in UK

Available for skin cancer patients through Cancer Drugs Fund

- PMLiVE

GSK submits Votrient for ovarian cancer in Europe

Pharma company hopes for extra indication for oncology product

Novartis building

Novartis says Afinitor fails liver cancer trial

Halts plans to file for approval in new indication

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

Bayer symbol

Bayer to research cancer immunotherapies with Compugen

Will develop drugs that boost response of body’s immune system to tumours

- PMLiVE

AZ inks $815m deal for FibroGen anaemia drug

Deal comes as company reveals second quarter performance

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links